Cargando…

A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis

SMARCA4-deficient thoracic sarcoma (DTS) is a rare malignancy defined by inactivating SMARCA4 mutations leading to protein loss. It was recently described as an aggressive disease with a dismal prognosis, mostly affecting young men with a history of heavy smoking. Histologically, SMARCA4-DTS is a po...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalaoui Rachidi, Siham, Firmin, Nelly, Elfadli, Mohamed, Essadi, Ismail, Belbaraka, Rhizlane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292728/
https://www.ncbi.nlm.nih.gov/pubmed/37378131
http://dx.doi.org/10.7759/cureus.39571
_version_ 1785062877194878976
author Lalaoui Rachidi, Siham
Firmin, Nelly
Elfadli, Mohamed
Essadi, Ismail
Belbaraka, Rhizlane
author_facet Lalaoui Rachidi, Siham
Firmin, Nelly
Elfadli, Mohamed
Essadi, Ismail
Belbaraka, Rhizlane
author_sort Lalaoui Rachidi, Siham
collection PubMed
description SMARCA4-deficient thoracic sarcoma (DTS) is a rare malignancy defined by inactivating SMARCA4 mutations leading to protein loss. It was recently described as an aggressive disease with a dismal prognosis, mostly affecting young men with a history of heavy smoking. Histologically, SMARCA4-DTS is a poorly differentiated tumor with rhabdoid or epithelioid features that can be distinguished from other soft tissue, and thoracic sarcomas by a higher tumor mutation burden (TMB) and the presence of smoking signatures, including KRAS, STK11, and KEAP1 mutations. Currently, there is no approved treatment for SMARCA4-DTS, which is known to be chemo-resistant, but more recent studies have shown some effectiveness with immune checkpoint inhibitors. We report the case of a 42-year-old man with a family history of cancer who was admitted to the hospital with acute respiratory distress and superior vena cava syndrome. He had been experiencing thoracic pain, dry cough, dyspnea, fatigue, and unintentional weight loss for a month. Imaging revealed multiple masses and lymph nodes in the chest, as well as pleural effusion. PET scan showed widespread metastases. A cervical lymph node biopsy confirmed the diagnosis of SMARCA4-deficient thoracic sarcoma. Unfortunately, his general condition did not allow an aggressive treatment. He was started on Pazopanib 800mg per day, but deteriorated rapidly and passed away. This report highlights the aggressive nature and unfavorable prognosis associated with SMARCA4-deficient thoracic sarcoma. Accurate diagnosis of this entity can be challenging due to its unique marker expression and unfamiliar histological features. Currently, there are no established treatment strategies for this condition; however, recent studies have shown promising results with immune checkpoint inhibitors and targeted therapies. Further research is necessary to identify the most effective treatment approaches for SMARCA4-DTS.
format Online
Article
Text
id pubmed-10292728
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102927282023-06-27 A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis Lalaoui Rachidi, Siham Firmin, Nelly Elfadli, Mohamed Essadi, Ismail Belbaraka, Rhizlane Cureus Pathology SMARCA4-deficient thoracic sarcoma (DTS) is a rare malignancy defined by inactivating SMARCA4 mutations leading to protein loss. It was recently described as an aggressive disease with a dismal prognosis, mostly affecting young men with a history of heavy smoking. Histologically, SMARCA4-DTS is a poorly differentiated tumor with rhabdoid or epithelioid features that can be distinguished from other soft tissue, and thoracic sarcomas by a higher tumor mutation burden (TMB) and the presence of smoking signatures, including KRAS, STK11, and KEAP1 mutations. Currently, there is no approved treatment for SMARCA4-DTS, which is known to be chemo-resistant, but more recent studies have shown some effectiveness with immune checkpoint inhibitors. We report the case of a 42-year-old man with a family history of cancer who was admitted to the hospital with acute respiratory distress and superior vena cava syndrome. He had been experiencing thoracic pain, dry cough, dyspnea, fatigue, and unintentional weight loss for a month. Imaging revealed multiple masses and lymph nodes in the chest, as well as pleural effusion. PET scan showed widespread metastases. A cervical lymph node biopsy confirmed the diagnosis of SMARCA4-deficient thoracic sarcoma. Unfortunately, his general condition did not allow an aggressive treatment. He was started on Pazopanib 800mg per day, but deteriorated rapidly and passed away. This report highlights the aggressive nature and unfavorable prognosis associated with SMARCA4-deficient thoracic sarcoma. Accurate diagnosis of this entity can be challenging due to its unique marker expression and unfamiliar histological features. Currently, there are no established treatment strategies for this condition; however, recent studies have shown promising results with immune checkpoint inhibitors and targeted therapies. Further research is necessary to identify the most effective treatment approaches for SMARCA4-DTS. Cureus 2023-05-27 /pmc/articles/PMC10292728/ /pubmed/37378131 http://dx.doi.org/10.7759/cureus.39571 Text en Copyright © 2023, Lalaoui Rachidi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pathology
Lalaoui Rachidi, Siham
Firmin, Nelly
Elfadli, Mohamed
Essadi, Ismail
Belbaraka, Rhizlane
A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis
title A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis
title_full A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis
title_fullStr A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis
title_full_unstemmed A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis
title_short A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis
title_sort case report of smarca4-deficient thoracic sarcoma: a rare and aggressive disease with a grim prognosis
topic Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292728/
https://www.ncbi.nlm.nih.gov/pubmed/37378131
http://dx.doi.org/10.7759/cureus.39571
work_keys_str_mv AT lalaouirachidisiham acasereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT firminnelly acasereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT elfadlimohamed acasereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT essadiismail acasereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT belbarakarhizlane acasereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT lalaouirachidisiham casereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT firminnelly casereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT elfadlimohamed casereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT essadiismail casereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis
AT belbarakarhizlane casereportofsmarca4deficientthoracicsarcomaarareandaggressivediseasewithagrimprognosis